Objectives

After participating in this educational activity, attendees should be able to:

1| Analyze the clinical rationale for using cell-free DNA (cfDNA) for non-invasive prenatal testing (NIPT) to determine fetal RhD status and detect single-gene disorders
2| Describe the technical principles and methodologies used to analyze cfDNA for applications beyond aneuploidy, specifically for fetal RhD prediction and identifying increased risk for single-gene disorders
3| Explain the clinical utility, limitations, and future considerations of expanded NIPT, including its potential impact on prenatal care for at-risk pregnancies. 

Presenter(s): 

Jeffrey Meltzer, MD, MBA
Senior Medical Director of Reproductive Health

 

NameRoleFinancial Relationship DisclosuresDiscussion of
Unlabeled/Unapproved Uses of
Drugs/Devices in Presentation?
Jeffrey Meltzer, MD, MBA Speaker/AuthorNatera – Medical Director & Stockholder No
Session date: 
09/25/2025 - 8:00am to 9:00am EDT
Location: 
Lundy Board Room & Zoom
759 Chestnut St
Springfield, MA 01199
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AAPA Category 1 CME credit
    Baystate Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. PA’s should only claim credit commensurate with the extent of their participation.
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC Contact Hours
  • 1.00 IPCE Credit Hour(s)
Please login or register to take this course.